The Family Man Gets His Day in Court: EGT Vs. Bluebird Bio

The Family Man Gets His Day in Court EGT Vs. Bluebird Bio

Last year, TrialSite published “A Familyman’s Battle Against the Forefront of the Capitalist Medicine: the Case of Errant Gene Therapeutics,” which depicted Patrick Girondi, an ex-commodity trader who grew up in Chicago’s tough southside in a rags to riches story—transforming into biotech entrepreneur driven by the calling to save his son Rocco—versus a polished, well-funded venture called Bluebird Bio. As it turned out in 1992, Girondi’s son Rocco (age 2 at the time) was diagnosed with the inherited blood disorder Thalassemia, a disease in which an individual’s body can’t generate enough hemoglobin. Those with moderate to severe cases often necessitate frequent blood transfusions and can result in an early death. After the diagnosis, Mr. Girondi retired from his lucrative trading career and dedicated his life to finding a cure for his son and others sharing this condition. He set out on a new pathway, learned the bio business and eventually founded Errant Gene Therapeutics, which licensed cutting-edge gene therapy from Memorial Sloan Kettering. Now before a tough but seemingly fair judge in Manhattan, at the heart of this the case are two very different claims.&nbs...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee